Aug. 14 at 12:18 PM
Stifel reitd
$ALKS Buy/
$42: At our Biotech Summer Summit, we sat down with
$ALKS CEO Richard Pops to discuss the prospects of the orexin program ahead of the full ph2 NT1 data at World SLEEP in September.
While the stock has traded somewhat sideways following the high-level topline release, we continue to believe in prospects of ALKS2680/alixorexton in narcolepsy and beyond.
Here,
$ALKS remains confident and discussed
(1) the consistency on efficacy across all measures, with best-in-class potential
(2) how at WORLD SLEEP they expect to share a robust dataset -- they see efficacy on cognitive/fatigue/quality-of-life endpoints as highly validating and
(3) how in non-NT1 patients, the dose-response curve may be shifted, so they don't expect to necessarily see safety/tolerability issues (i.e. meaningfully higher AEs) even with higher dosing.
We also briefly touched on the potential to move
beyond sleep disorders, along with management's views on MFN, and tariffs.
$BIIB $AXSM $JAZZ $CNTA #SLEEP2025
